LEADER 04186nam  2201153z- 450 
001 9910557498903321
005 20210501
035   $a(CKB)5400000000042842
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68603
035   $a(oapen)doab68603
035   $a(EXLCZ)995400000000042842
100   $a20202105d2020      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aDrug Delivery of siRNA Therapeutics
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020
215   $a1 online resource (288 p.)
311 08$a3-03936-200-3 
311 08$a3-03936-201-1 
330   $aThe new frontier of pharmaceutical sciences is gene therapy, which is the use of molecules able to interact directly with the expression of the genetic material of the patient as well as of the disease-causing guest (bacteria, virus, parasites, and tumor cells). Among the molecules of interest for gene therapy, a relevant role is played by small interfering RNA (siRNA) molecules able to interfere with the expression of genes of interest for some diseases. However, siRNA molecules, even if they are powerful as drugs, are difficult to deliver since they are sensitive to enzymes present in plasma and they are large and negatively charged, so are difficult to administer into the cell nuclei, since the cell walls are scarcely permeable to large molecules and are also negatively charged. Therefore, the focus of research on siRNA-based therapies is their delivery, which can be performed by chemical modification, association with aptamers or polycations, or embedding them into properly designed liposomes. This book is centered on the more recent development in siRNA delivery techniques toward the clinical applications of this potent class of drugs.
606   $aMedicine$2bicssc
610   $aAKT
610   $aamphiphilic dendrons
610   $aangiogenesis
610   $aantitumor effect
610   $aaptamers
610   $aasthma
610   $aBCL2
610   $aBIRC5/survivin
610   $abreast cancer
610   $acancer
610   $acarbonate apatite
610   $acationic cholesterol derivative
610   $acationic liposome
610   $aclinical trials
610   $acovalent dendrimers
610   $adelivery
610   $adrug co-delivery
610   $adrug delivery
610   $aendoglin
610   $aendothelial cells
610   $aERBB2
610   $afolate
610   $afolate receptor
610   $agene knockdown
610   $agene silencing
610   $aindocyanine green
610   $aintracellular release
610   $airon oxide
610   $alight-activated release
610   $alipid
610   $aliposome
610   $aliposomes
610   $amagnetic nanoparticle
610   $amethotrexate
610   $amigration
610   $amixed micelles
610   $an/a
610   $aNABDs
610   $ananoparticle
610   $ananoparticles
610   $ananovectors
610   $aoligonucleotide delivery
610   $aoral cancer
610   $aovarian cancer
610   $aPAMAM dendrimers
610   $apegylation
610   $aPEI
610   $apeptide
610   $apoly(ethylene) imine
610   $apolyamine
610   $apolyaspartamide
610   $apolymer
610   $apolyplexes
610   $aproliferation
610   $aRNA
610   $aRNAi therapeutics
610   $aself-assembling
610   $asiRNA
610   $asiRNA delivery
610   $aSTAT6
610   $atargeted delivery system
610   $atumor xenograft
610   $atumor-targeting
610   $atyrosine-modification
610   $aVEGFA
610   $aVEGFR1
615  7$aMedicine
700   $aLamberti$b Gaetano$4edt$023147
702   $aAngela Barba$b Anna$4edt
702   $aLamberti$b Gaetano$4oth
702   $aAngela Barba$b Anna$4oth
906   $aBOOK
912   $a9910557498903321
996   $aDrug Delivery of siRNA Therapeutics$93021406
997   $aUNINA